1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Celyad Oncology S.A.

Celyad Oncology S.A.

CLYYF
Celyad Oncology S.A.US flagOther OTC
0.20
USD
- -
- -
8.95MMarket Cap
Celyad Oncology S.A.
CLYYF
(Other OTC)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.01
- -
0.02
- -
1.07
0.37
0.28
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.44
-2.14
-3.53
-2.44
-3.43
-2.53
-5.86
-3.36
-2.29
-1.23
-1.7
-1.81
-0.33
-0.14
0.02
-1.15
Basic EPS, GAAP
- -
-1.42
-2.72
-2.67
-3.32
-2.84
-4.71
-2.6
-2.3
-2.01
-1.73
-1.25
-0.63
-0.14
-0.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.13
-2.32
-3.48
-6.9
-7.98
-9.8
-15.18
-15.82
-2.07
-16.82
-14.77
-12.01
-12.65
-8.59
-8.28
-10.98
Book Value per Share
-0.32
-1.88
1.83
2.43
7.38
4.43
1.15
1.74
0.75
-0.37
0.48
0.15
0.23
- -
0.06
-0.27
Tangible Book Value per Share
6
6
4
7
8
9
10
11
13
14
16
23
26
41
43
22
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
10
4
3
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-33,710.77
-17,098.65
- -
-13,621.23
-977,233.33
-260.98
-768.11
-1,007.61
-489,550
-522,020
- -
- -
-9,238.24
-3,154.3
-6,400
- -
Operating Margin (%)
3
1
1
1
1
2
9
1
2
2
2
1
1
- -
- -
- -
Depreciation Expense
-9
-14
-14
-16
-29
-24
-56
-37
-29
-17
-27
-41
-8
-6
1
-26
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-33,916.42
-25,044.91
- -
-11,269.18
-970,466.67
-235.78
-1,593.08
-1,201.51
-477,200
-344,080
- -
- -
-8,282.35
-3,131.18
3,952.38
- -
Profit Margin (%)
-2
-1
19
27
98
74
28
42
31
8
20
4
8
4
2
8
Working Capital
- -
- -
- -
- -
- -
1
1
1
3
3
2
- -
1
1
- -
1
LT Debt
1
-2
17
27
111
91
48
56
46
31
44
4
6
1
2
31
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-69.78
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.25
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
58
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'21
Mar'22
Jun'22
Total Current Assets
34
26
19
Cash, Cash Equivalents & STI
30
21
14
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
10
11
Payables & Accruals
8
6
8
ST Debt
1
1
1
Deferred Revenue
1
- -
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.23%
56.31%
376.71%
Free Cash Flow
-6.13%
-17.41%
19.01%
Net Income, GAAP
-9.32%
-23.23%
-114.25%
Sales/Revenue/Turnover
- -
- -
-88.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.33
2024
- -
- -
- -
- -
-0.14
2025
- -
- -
- -
- -
0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
eFFECTOR Therapeutics, Inc. (EFTR)
Marizyme, Inc. (MRZM)
Santhera Pharmaceuticals Holding AG (SANN.SW)
Nuvation Bio Inc. (NUVB)
Silence Therapeutics plc (SLN)
Freeline Therapeutics Holdings plc (FRLN)
Business
Celyad Oncology S.A. (Ticker: CLYYF) develops allogeneic CAR T-cell therapies for the treatment of hematological and solid cancers. The company offers proprietary platforms including the allogeneic CAR T technology platform, which engineers non-patient-derived T-cells to avoid graft-versus-host disease; the RNA Switch platform for transient CAR expression; and the Mask platform to mitigate cytokine release syndrome risks. Its lead product candidate, CYAD-101, targets B-lymphoma via NKG2D receptor targeting; CYAD-200 advances off-the-shelf CAR T-cells for colorectal cancer; CYAD-1901 employs RNA Switch for HER2-positive solid tumors; and CYAD-1801 focuses on claudin 18.2-positive gastric cancers. Celyad Oncology operates primarily in Europe and the United States, with headquarters in Mont-Saint-Guibert, Belgium, founded in 2007 as a spin-off from Ludwig Cancer Research. In recent developments, the company completed a merger with 180 Life Sciences in 2024, shifting strategic focus toward fibrosis treatments while retaining oncology assets; announced a reverse stock split and Nasdaq uplisting efforts in early 2025; and initiated a Phase 1 trial expansion for CYAD-200 in combination therapies. Celyad Oncology serves pharmaceutical partners and clinical trial patients in the biotechnology sector, with subsidiaries including Celyad Oncology USA Inc..